Product image of Hypablo (Metoprolol Tartrate) supplied by GNH India

Hypablo

Active Ingredient:
Metoprolol Tartrate
Origin:
EU

Hypablo (Metoprolol Tartrate)

Metoprolol Tartrate, the active ingredient in Hypablo, is a beta blocker presented as a tablet for oral use. It is employed to manage high blood pressure, relieve angina, improve outcomes after myocardial infarction, and support treatment of certain heart failure patients.

GNH India supplies Hypablo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance and regulatory compliance across global markets.

Manufacturer / TM Owner

Zentiva, K.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metoprolol Tartrate is a selective β1‑adrenergic blocker used in cardiovascular disease management.

  • Hypertension: lowers blood pressure by reducing heart rate and cardiac output.
  • Angina pectoris: decreases myocardial oxygen demand, relieving chest pain episodes.
  • Myocardial infarction: improves survival by limiting heart workload and preventing arrhythmias after an acute event.
  • Heart failure: enhances ventricular function and reduces symptoms in patients with reduced‑ejection‑fraction heart failure.

How It Works

  • Metoprolol Tartrate selectively antagonizes β1‑adrenergic receptors in cardiac tissue, blocking the actions of endogenous catecholamines such as norepinephrine. This inhibition reduces cyclic AMP formation, leading to decreased heart rate, contractility, and conduction velocity, which collectively lower myocardial oxygen consumption and systemic blood pressure while sparing β2 receptors in bronchial and vascular smooth muscle.

Side Effects

Metoprolol Tartrate may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Fatigue or tiredness
  • Dizziness or light‑headedness
  • Gastrointestinal upset (nausea, abdominal discomfort)

Serious or Rare Side Effects

  • Severe bradycardia or heart block
  • Marked hypotension with fainting risk
  • Bronchospasm in patients with asthma or COPD

Precautions & Warnings

When prescribing Metoprolol Tartrate, clinicians should consider several safety measures.

  • Assess cardiac function: evaluate heart rate and blood pressure before initiating therapy.
  • Monitor for bronchospastic disease: use cautiously in patients with asthma or COPD.
  • Adjust dose in renal impairment: consider reduced dosing in patients with decreased renal clearance.
  • Review concomitant medications: avoid combining with other β‑blockers or drugs that may exacerbate bradycardia.
  • Pregnancy category B: use only if benefit outweighs potential risk.
  • Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Metoprolol Tartrate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Combined use with other β‑blockers: may cause excessive bradycardia or heart block.
  • Concomitant calcium channel blockers (verapamil, diltiazem): increase risk of AV conduction delays.
  • Non‑selective β‑blockers with insulin or oral hypoglycemics: mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely)

  • Antihypertensives (ACE inhibitors, diuretics): may enhance hypotensive effect.
  • Antidepressants (SSRIs, SNRIs): potential for additive bradycardia.
  • NSAIDs: may reduce antihypertensive efficacy.

Frequently Asked Questions

Hypablo contains Metoprolol Tartrate, a selective β1‑adrenergic blocker that is prescribed to treat high blood pressure, relieve chest pain from angina, improve survival after a heart attack, and manage symptoms of chronic heart failure in appropriate patients.

Metoprolol Tartrate works by competitively blocking β1‑adrenergic receptors in the heart. This reduces the effects of norepinephrine and epinephrine, leading to slower heart rate, decreased contractility, and lower cardiac output, which together lower blood pressure and myocardial oxygen demand.

The dosage of Hypablo is individualized by the prescribing clinician based on the patient’s condition, response, and tolerance. The prescriber determines the appropriate strength, frequency, and titration schedule in accordance with clinical guidelines.

Metoprolol Tartrate is classified as pregnancy category B, indicating that animal studies have not shown risk but there are limited human data. It should be used only if the potential benefit justifies any possible risk to the fetus, and breastfeeding mothers should consult their physician.

To request Hypablo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Hypablo (Metoprolol) is a cardio‑selective β1 blocker, offering a favorable profile for patients with respiratory disease compared with non‑selective agents like propranolol. Compared with atenolol, Metoprolol has a shorter half‑life and may provide more flexible dosing, though both share similar efficacy for hypertension and angina.

Hypablo tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Hypablo is taken orally with a glass of water, usually once or twice daily as directed by the prescriber. It can be taken with or without food, but consistency with meals may help reduce gastrointestinal discomfort.

Serious risks include severe bradycardia or heart block, marked hypotension that can cause fainting, and bronchospasm in patients with asthma or chronic obstructive pulmonary disease. Patients should be monitored for these events, especially during dose initiation or escalation.

Hypablo is contraindicated in patients with known hypersensitivity to metoprolol or other beta blockers, those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and individuals with uncompensated heart failure or severe peripheral vascular disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metoprolol Tartrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT